cyrilzakka/clinical-trials huggingface dataset:
Effect Of Dry Needling On Quality Of Life In Patients With Trigger Fingers

This study will be conducted to investigate the effect of dry needling on quality of life in patients with trigger finger

Trigger finger (TF) is one of the most prevalent causes of hand disability and is a common cause of referral to orthopedic clinics. Trigger finger is tenosynovitis of the flexor sheaths that typically occurs in the 4th finger and thumb as a result of repetitive use. The incidence of TF is 28:100,000 per year or lifetime risk of 2.6% in the general population. It has the highest incidence being between 52 and 62 years more in women (75%). Thumb and fourth digit (ring finger) are the most commonly affected fingers.

Dry needling (DN) is a relatively new technique used by physical therapists to treat myofascial trigger points (MTrPs) and various pain syndromes. Dry needling is defined as a "skilled intervention using a thin filiform needle to penetrate the skin that stimulates myofascial TrPs, muscles, and connective tissue for the treatment of musculoskeletal pain disorders. DN has analgesic and anti-inflammatory effects, it is commonly used to relieve pain and reduce inflammation.

Eligibility Criteria:
Inclusion Criteria:

* 40 patients all have trigger fingers lasting at least 4 weeks.
* Both gender will be included
* Age of patients will be 45-75 years old
* Pain and tenderness at the position of A1 pulley.
* Nodule palpation, pain, and discomfort when flexing and extending the finger, presence of a clicking sound at the time of flexion or extension of the finger, snapping or locking of the finger.
* Willing and able to complete study procedures.

Exclusion Criteria:

* Participants with diabetes mellitus.
* History of trauma, and rheumatoid arthritis.
* Dialysis treatment.
* fingers with a history of local gouty/pyogenic disease.
* Major hand trauma and fear of needles.
* Any contraindication for deep dry needling such as anticoagulants, infections, bleeding, or psychotic conditions tumors, calcium deposits, or severe osteoarthritis.
Sharing History Through Active Reminiscence and Photo-imagery (SHARP) Pilot Program

SHARP is a neighborhood-based and technology-supported approach to brain health for older Black adults that integrates walking and image-prompted social reminiscence to maintain or improve brain health.

The SHARP study tests the feasibility, usability, and cultural relevance of an android application-supported walking study for brain health among older Black adults. The SHARP walking application enables the seamless integration of the brain-healthy behaviors of walking, social engagement, and reminiscence. Methods: Over the course of 24 weeks in the rapidly gentrifying historically Black neighborhoods of Portland, Oregon, triads aim to complete three 1-mile walks per week. The SHARP application is preprogrammed with 72 themed, 1-mile routes, accessible via a group tablet device. At three points along each route, GPS-triggered "Memory Markers" (historical images of local Black culture) appear on the walking application, serving as prompts for conversational reminiscence as triads walk. Walking reminiscence sessions are recorded for inclusion into a digital oral history archive.

Eligibility Criteria:
Inclusion Criteria:

* Self-identified African American
* \> 55 years old
* A long-time resident (\>10 cumulative years) of Portland's historically black neighborhoods (currently or in within the last 10 years)
* Without symptoms of and without a diagnosis of Alzheimer's Disease (they must be preclinical subjects),
* Without serious cognitive impairment and must score \> 24 on the age-education adjusted Mini-Mental State Exam
* Has internet access in the home.
* Able to ambulate independently, without walking aids
* Able to sustain walking at a moderate pace for 45 minutes.

Exclusion Criteria

* Serious or unstable medical condition (such as, but not limited to, cardiovascular disease, pulmonary disease, or severe arthritis) where participation in the trial would, in the opinion of the investigator, pose a significant health risk to the subject.
* Diagnosis of Alzheimer's disease, vascular dementia, Parkinson's disease, or other dementing illness.
Preventing Suicide With Safe Alternatives for Teens and Youths (SAFETY)

Suicide is the leading cause of death in the age span 10-19 years in Sweden. The most robust predictor of future suicide attempt and suicide death is prior suicide attempt. Yet, most youths presenting with suicidal behavior to the Child and Adolescent Mental Health Services (CAMHS) in Stockholm, Sweden are not offered evidence-based care directly targeting suicide risk. Safe Alternatives for Teens and Youths (SAFETY) is a novel scalable suicide prevention program designed to fill this critical gap. SAFETY is a cognitive behavioral family treatment incorporating elements from Dialectical Behavior Therapy and Multisystemic Therapy. SAFETY has shown promise in reducing suicide attempts in two small-N trials. In a randomized controlled feasibility trial, the investigators will examine the feasibility of SAFETY and an active control condition named Supportive Therapy at post-treatment, 3 and 12 months after treatment on youth suicidal behavior. Evaluations of feasibility, acceptability, and safety based on data from this pilot trial will guide and inform the design of a full-scale randomized controlled trial.

Research questions:

1. Is it feasible (operationalized as participation in treatment, completed homework assignments, reported adverse events) to offer SAFETY to youths with suicidal behavior and their caregivers within the CAMHS?
2. Is it feasible (operationalized as participation in treatment, completed homework assignments, reported adverse events) to offer Supportive Therapy as an active control treatment to youths with suicidal behavior and their caregivers within the CAMHS?
3. Is the planned procedure and design (recruitment, blinded assessors, randomization and data attrition) of the study feasible?
4. What are the proportions of suicidal behavior in the group randomized to SAFETY group and the group randomized to Supportive Therapy, respectively?
5. Is participation in SAFETY and Supportive Therapy associated with improved emotion regulation, perceived social support, and family function, and how large are the effects (suggested treatment processes)?
6. Is participation in SAFETY and Supportive Therapy associated with improvements in nonsuicidal self-injury, depression, anxiety, and other outcomes, and how large are the effects (outcomes)?
7. How do the youths and caregivers experience participation in SAFETY and Supportive Therapy, respectively?

Eligibility Criteria:
Inclusion Criteria:

* Suicidal behavior (defined as suicide attempt, interrupted suicide attempt, aborted suicide attempt, or preparatory behavior) in the last 3 months
* Age 10-17 years
* At least one primary caregiver willing to participate in treatment

Exclusion Criteria:

* Symptoms requiring other immediate treatment (e.g. psychosis, severe anorexia nervosa)
* Ongoing treatment with DBT
* Individual or life circumstances that could complicate or make treatment participation impossible, or that require immediate intervention (e.g., violence in close relationships; intellectual disability)
* Insufficient understanding of the Swedish language
RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer

This study will conduct a multicenter, open, prospective clinical trial to observe the RecurIndex to assist in predicting the risk of recurrence in patients with early-stage Luminal-type breast cancer. The aim of this study is to validate the predictive effect of the RecurIndex on the risk of recurrence in women with early-stage Luminal-type breast cancer in China.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old, ≤ 70 years old.
* Eastern Cooperative Oncology Group (ECOG) ≤ 2.
* Postoperative pathology is clearly diagnosed as invasive breast cancer.
* Estrogen receptor (ER) or progesterone receptor (PR) positive, HER2 negative.
* Available with Formalin-Fixed and Parrffin-Embedded (FFPE) tumor tissue.
* Stage I-II patients who have received surgery (breast-conserving or mastectomy) and the pathological staging is pT1-2N0-1M0 or pT3N0M0.
* The patient had not received systemic systemic treatment (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy) before enrollment.
* Signed an informed consent form.

Exclusion Criteria:

* Breast cancer patients whose clinical or pathological stage is T4, N2-3 or M1.
* Known human immunodeficiency virus infection (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases.
* Other psychiatric disorders that may interfere with the judgment of the study results, or abnormal laboratory tests; and who, in the judgment of the investigator, are considered unfit to participate in the study.
* Patients with double breast cancer.
* Severe/uncontrolled intercurrent diseases/infections.
* Subjects with allogeneic organ transplants requiring immunosuppressive therapy.
* Hormone receptors ER and PR are negative (any detectable estrogen and progesterone receptors do not express or express \<1%) and/or HER2 overexpression/amplified by FISH detection.
* Not suitable for hormone receptor modulators (e.g. tamoxifen) and adjuvant endocrine other drug therapy.
Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?

Clopidogrel pre-treatment before planned percutaneous coronary intervention was proved to reduce periprocedural complications. However, the vast majority of patients in the current interventional cardiology practice do not undergo planned PCI, but rather "ad-hoc" PCI performed immediately after coronary angiography . Whether clopidogrel should be administered as pre-treatment to all patients undergoing elective CAG with the aim to ensure therapeutic levels at the time of possible ad-hoc PCI is not known.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years
2. Elective CAG for suspected or proven coronary artery disease (stable forms or fully stabilized acute coronary syndrome)
3. Signed written informed consent

Exclusion Criteria:

1. Thienopyridine treatment in previous two weeks
2. Contraindication for clopidogrel
3. CAG scheduled less than 6 hours after potential randomization
4. Clinically significant bleeding (i.e. with hemoglobin fall by \> 50 g/l and/or requiring transfusions or surgery) in previous 3 months.
Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation

The purpose of this study is to predict the occurrence of paroxysmal atrial fibrillation by finding high-risk group from normal sinus rhythm ECG through artificial intelligence-based prediction algorithm.

This study is a multi-center, prospective observational validation study. Patients aged 18 or above who are hospitalized at our hospital or who visited the outpatient clinic with arrhythmia symptoms (such as palpitation) after the clinical research approval will be enrolled. The normal sinus rhythm electrocardiogram (ECG) at the time of participation in the study is recorded and put into the artificial intelligence prediction algorithm. The result of risk stratification is blinded and will not be informed to both the research director and subjects. After applying wearable devices to the subject, the ECG recorded for the first week is analyzed to confirm the occurrence of paroxysmal atrial fibrillation (the gold standard for diagnosis of atrial fibrillation). When the wearable devices are removed, the 12 lead electrocardiogram will be taken again, and if it shows normal sinus rhythm electrocardiogram, then it will be put into the artificial intelligence prediction algorithm to calculate the result as well.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be above 20 in age
* Participants are patients with symptom of arrhythmia who visited outpatient clinic or who have been hospitalized

Exclusion Criteria:

* Excluding patients with cardiac implantable electronic device such as pacemakers, implantable defibrillators (ICD), or cardiac resynchronization therapy (CRT).
* Excluding pregnant women and lactating women.
Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult subjects. This is the first clinical study of ID110521156.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects aged 19 to 50 years at the time of Screening.
* Body mass index (BMI) within 18.5 to 29.9 kg/m2; and a total body weight ≥ 40 kg, ≤ 90 kg
* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
* For female subjects, not pregnant or lactation women, or naturally menopausal (spontaneous amenorrhea for at least 12 months) or surgically infertility (bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy etc).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal(including pancreatitis), cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.
* Treatment with an investigational drug (including a bioequivalence study) within 6 months prior to the scheduled date of administration of the investigational product.
* Fertile male subjects who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for at least 3 months after the last dose.
Ureteroscopic Lithotripsy in the Reverse Trendelenburg Position for Upper Ureteral Stones

This study investigated a previously unassessed operating position for ureteroscopic holmium laser lithotripsy in patients with upper ureteral stone. The reverse Trendelenburg position can reduce migration and improve the stone free rate (SFR). Moreover, less utilization of flexible ureteroscope and hospital stay in reverse Trendelenburg position can reduce the medical cost. Therefore, it can be safely used as an optional surgical method for the treatment of upper ureteral stones.

With the rapid development of urological endoscopy technology, minimally invasive surgery has replaced open surgery in ureteral stones. The majority of upper ureteral stones are treated with endoscopic techniques. In the last 10 years, URSL (Ureteroscopic Lithotripsy) has surpassed SWL (Shock-wave lithotripsy) with its wide use \[1\]. While URSL was considered in the foreground according to SWL for proximal ureteral stones larger than 1 cm, today it is recommended with equal efficiency and safety with SWL for stones smaller than 1 cm \[2\]. However, migration of stones to renal calyces is a common problem during ureteroscopic treatment of upper ureteral stones. Migration can be caused by many factors such as the momentum of the laser pulse, stone manipulation of the laser fiber, fluid irrigation pressure and the increase of ureteral dilatation. The degree of migration varies according to the impaction level of the stone and the location in the ureter \[3\].

The migration of the stone to the renal pelvis and calyces increases the operation time and cost \[4-6\]. Recently published American Urological Association Guidelines reported that ureteroscopy of ureteral stones performed an average of 1.33 procedures per patient \[7\]. In order to prevent stone migration, tools have been developed that are used in the proximal of the stone or that interfere with the stone in the kidney after retreatment. Although these developed devices are effective, it has been determined that their additional use causes an additional cost of $ 278 per case as well as extending the operation time \[8\]. In addition, placing an anti-migration device in the ureter can restrict laser fiber manipulation. Ureterorenoscopes (Flexible URS) that can flex 270 degrees, which can be used to intervene in the stone after retraction into the kidney, have made a very serious improvement, but these devices are not yet available in all centers, especially in developing countries.

There is an in-vitro study using polymer tubes that predict that the proximal ureter should stay higher than the distal ureter in order to prevent retrograde in proximal ureteral stones \[9\].

Eligibility Criteria:
Inclusion Criteria:

* Obstructive upper ureteral stones

Exclusion Criteria:

* Presence of stent in the ureter at the beginning of the operation
* Serum creatinine value\> 1.5 mg / dL
* Pathological ureteral strictures
* Previous open surgery history for the ureteral stone
* Previous pelvic radiotherapy history
* Pregnancy
* Solitary kidney
Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole

The primary objective of this study is to determine if trabecular or cortical volumetric bone mineral density (vBMD) change over time in postmenopausal breast cancer patients who are prescribed Anastrozole, as measured by pQCT at the proximal and distal radius and tibia.

In bone, where estrogen is required to maintain density, there is indication of increased turnover in patients prescribed Aromatase Inhibitors. However, there are no studies to date that prospectively quantify the impact of Aromatase inhibitors on bone quality. Furthermore, the actual effects and clinical significance of adjuvant chemotherapy and supportive medications on bone quality in women with breast carcinoma is unknown. The current study proposes to prospectively assess novel skeletal health outcomes, namely trabecular structure (connectivity, hole size) and bone geometry (bone area, cortical thickness) among women with breast cancer being treated with Anastrozole. Not only will the current study provide a better understanding of the changes in bone quality and muscle mass after Anastrozole treatment, it will provide important information about the development of secondary skeletal complications in this population. Therefore, the potential to collect data prospectively from a cohort of individuals with breast cancer being treated with Anastrozole represents an important step to advance knowledge in this area. Also, by examining bone quality and secondary complications in a diverse cohort of patients who vary with respect to radiation therapy, chemotherapy and additional medications, we can begin to identify patterns of musculoskeletal change and predictors of these changes.

Eligibility Criteria:
Inclusion Criteria:

Group 1: Treatment Group

* Postmenopausal breast cancer patients (stage 1 and 2)
* Non-institutionalized
* Prescribed Anastrozole within the preceding 1-2 weeks
* Ambulatory
* Ability to read and comprehend study protocol and informed consent

Group 2: Control Group

* Healthy, age-matched postmenopausal women
* Non-institutionalized
* Ambulatory
* Ability to read and comprehend study protocol and informed consent

Exclusion Criteria:

* Prior Tamoxifen or Raloxifene therapy
* Known congenital metabolic bone disease (e.g., osteogenesis imperfecta)
* Concomitant treatment with corticosteroids
* Patients with a history of endocrine disorders or surgical parathyroidectomy
* Patients with disorders known to affect bone metabolism including diabetes mellitus, systemic lupus erythematosus, Cushing's disease, hyperparathyroidism, chronic liver disease, chronic renal failure, Paget's disease
* Conditions preventing pQCT measurement (e.g., unable to lie flat or still for 15 minutes)
* Geographically inaccessible for follow-up
The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal

In the design of extracorporeal carbon dioxide removal (ECCO2R) combined with continuous renal replacement therapy (CRRT) equipment, in model of continuous veno-venous hemofiltration (CVVH) , the HCO3- concentration in the pre membrane lung blood is diluted by the replacement solution, and a decrease in HCO3- leads to a decrease in PCO2. On the other hand, in continuous veno-venous hemodialysis (CVVHD), HCO3- in post membrane blood will exchange interaction. The exchange results of HCO3- determine the impact of CVVHD on the CO2 removal efficiency of the ECCO2R combined CRRT system. This study aims to investigate the effects of CVVH and CVVHD on in vitro CO2 clearance efficiency.

In the design of extracorporeal carbon dioxide removal (ECCO2R) combined with continuous renal replacement therapy (CRRT) equipment, the pre dilution replacement solution for continuous veno-venous hemofiltration (CVVH) enters the extracorporeal bloodstream upstream of the membrane lung, so the HCO3- concentration in the pre membrane lung blood is diluted by the replacement solution. HCO3- and dissolved CO2 are in a dynamic and rapid equilibrium state, and a decrease in HCO3- leads to a decrease in PCO2. On the other hand, in continuous veno-venous hemodialysis (CVVHD), the blood after the membrane needs to undergo material exchange with the dialysate through a filter. The dialysate is usually HCO3- with normal plasma concentration, so HCO3- in post membrane blood will exchange interaction. The exchange results of HCO3- determine the impact of CVVHD on the CO2 removal efficiency of the ECCO2R combined CRRT system. This study aims to investigate the effects of CVVH and CVVHD on in vitro CO2 clearance efficiency.

Eligibility Criteria:
Inclusion Criteria:

* Using Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy
* 18 years ≤ age ≤ 85 years;

Exclusion Criteria:

* Severe hemodynamic instability (increased dosage of vasoactive drugs or MAP ≤ 65mmHg within two hours);
* Severe electrolyte deficiency (including severe hyponatremia (blood sodium\<130mmol/L) and hypokalemia (blood potassium\<3.0mmol/L));
* Participate in other intervention studies within 30 days;
* Do not consent this research
PerClot to Control Bleeding in Endoscopic Sinus Surgery

A prospective, single centre, single arm study designed to collect clinical data on PerClot when used in subjects undergoing endoscopic sinus surgery.


Eligibility Criteria:
Inclusion Criteria:

* Subjects having Endoscopic Sinus Surgery
* Subjects who will have PerClot used as a haemostatic agent
* Subjects willing and able to give consent
* Subjects over 18 years old

Exclusion Criteria:

* Subjects unable or unwilling to give consent for their data to be collected